Treatment of lysosomal storage disorders
- 30 August 2003
- Vol. 327 (7413) , 462-463
- https://doi.org/10.1136/bmj.327.7413.462
Abstract
Footnotes Competing interests AM has received support from Genzyme Corporation, TKT, and Actelion for travel expenses, research, or consultancy, and CL has received support for patients' support projects, travel expenses, and honorariums for speaking engagements.Keywords
This publication has 7 references indexed in Scilit:
- New developments in the management of Anderson-Fabry disease.QJM: An International Journal of Medicine, 2002
- Prevalence of Anderson-Fabry Disease in Male Patients With Late Onset Hypertrophic CardiomyopathyCirculation, 2002
- Enzyme-replacement therapy for Anderson-Fabry diseaseThe Lancet, 2001
- Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's DiseaseNew England Journal of Medicine, 2001
- Enzyme Replacement Therapy in Fabry DiseaseJAMA, 2001
- Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesisThe Lancet, 2000
- Anderson-Fabry disease.BMJ, 1988